Does Doxorubicin have serious side effects? Common adverse reactions and preventive measures

Doxorubicin (Doxorubicin) is a broad-spectrum anthracycline anti-tumor drug that is widely used in the treatment of breast cancer, ovarian cancer, lymphoma, leukemia and other malignant tumors. Its main mechanism of action is to embed DNA double-stranded structure, inhibit topoisomerase II activity, hinder DNA replication and transcription, and at the same time generate free radicals and induce tumor cell apoptosis, thereby achieving anti-cancer effects. Despite its remarkable efficacy, doxorubicin is highly toxic and needs to be strictly managed in clinical practice to balance efficacy and safety.

The most common and clinically significant side effect of doxorubicin is myelosuppression, manifested by neutropenia, thrombocytopenia, and anemia. Neutropenia can increase the risk of infection, and sepsis may occur in severe cases. Low platelets increase the risk of bleeding, and anemia may cause symptoms such as fatigue and palpitations. Preventive measures include regular blood monitoring before and after each chemotherapy cycle, and adjusting the dose or delaying chemotherapy based on the blood picture. At the same time, for high-risk patients, granulocyte colony-stimulating factor (G-CSF) can be given for supportive treatment to reduce the incidence of infection.

Doxorubicin has cumulative cardiotoxicity, mainly manifested as myocardial damage, arrhythmia and risk of heart failure. The occurrence of cardiotoxicity is closely related to cumulative dose, previous heart disease, and the use of combined chemotherapy drugs. Clinically, it is recommended to conduct electrocardiogram and echocardiographic evaluation before using doxorubicin, and to review cardiac function regularly during treatment. If patients have cardiac dysfunction, dose reduction, longer intervals, or the use of liposomal formulations may be considered to mitigate cardiotoxicity. In addition, the application of cardioprotective drugs such as ACEI or β-blockers can also reduce myocardial damage to a certain extent.

Doxorubicin often causes gastrointestinal side effects such as nausea, vomiting, oral ulcers and loss of appetite, seriously affecting patients' quality of life. Prevention and relief measures include: using 5-HT3 receptor antagonists or NK1 receptor antagonists for preventive anti-nausea treatment, maintaining small and frequent meals, a light diet, and paying attention to oral hygiene. If necessary, topical drugs can be used to relieve oral ulcers. For patients with severe gastrointestinal reactions, chemotherapy can be appropriately delayed or the dose adjusted to improve tolerance.

Doxorubicin can cause significant hair loss (including eyebrows and eyelashes), skin pigmentation, hand-foot syndrome and other reactions. Although hair loss usually recovers gradually after treatment, it has a greater psychological impact on patients. Care recommendations include using mild toiletries, avoiding dyes, perms and harsh chemicals, and wearing a hat, scarf or wig to protect the scalp during treatment and relieve psychological stress. People with hand-foot syndrome should keep their hands and feet clean, avoid high temperatures and friction, and use topical moisturizing and soothing ointments.

The metabolism of doxorubicin mainly depends on the liver, and renal excretion also participates in a certain proportion. Therefore, patients with abnormal liver and renal function should use it with caution. Elevated liver enzymes, jaundice, and renal impairment may occur. Clinically, it is recommended to evaluate liver and kidney function before chemotherapy and adjust the dose if necessary. Some patients may also develop neurotoxicity, fever, fatigue, and local phlebitis, and require supportive treatment and monitoring measures based on symptoms.

A comprehensive evaluation should be conducted before using doxorubicin, including blood picture, liver and kidney function, heart function and previous medication history. During chemotherapy, patients should maintain regular review and report abnormal symptoms in a timely manner. Medical staff should guide patients to identify early side effects, such as fever, bleeding, difficulty breathing, etc., and take timely intervention measures. Through dose adjustment, supportive treatment and life management, most side effects can be effectively controlled while ensuring anti-tumor efficacy.

Overall, as a highly effective anti-tumor drug, the side effects of doxorubicin cannot be ignored. However, through standardized management, individualized dose adjustment and preventive supportive treatment, its safety can be controlled within a controllable range. In clinical practice, treatment plans should be formulated based on the patient's constitution, tumor type and past tolerance, while emphasizing patient education and follow-up monitoring to achieve a balance between efficacy and safety to the greatest extent. Although doxorubicin has serious side effects, scientific management and individualized strategies can enable patients to obtain the best treatment benefits.

Reference materials:https://www.drugs.com/